Buspirone Treatment for Marijuana Dependence
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | September 2009 |
| End Date: | May 2016 |
Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated
pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy
of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency
management (CM) intervention and motivational enhancement therapy (MET) will be incorporated
to encourage study engagement and retention. It is hypothesized that buspirone combined with
MET and CM will reduce the percent of marijuana-positive urine drug screen results in
marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy
of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency
management (CM) intervention and motivational enhancement therapy (MET) will be incorporated
to encourage study engagement and retention. It is hypothesized that buspirone combined with
MET and CM will reduce the percent of marijuana-positive urine drug screen results in
marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.
Inclusion Criteria:
- Must meet DSM-IV criteria for marijuana dependence.
- Must be between the ages of 18 and 65 years.
- If female and of childbearing potential, must agree to use acceptable methods of
birth control for the duration of the trial.
- Must consent to random assignment, and be willing to commit to psychosocial
behavioral and medication treatment.
- Must be able to read and provide informed consent.
Exclusion Criteria:
- Women who are pregnant, nursing, or plan to become pregnant during the course of the
study.
- Must not have a history of or current psychotic disorder, bipolar disorder, or eating
disorder.
- Must not pose a current suicidal or homicidal risk.
- Must not meet current criteria for major depression.
- Must not have evidence or history of serious hematologic, endocrine, cardiovascular,
pulmonary, renal, gastrointestinal or neurologic disease.
- Must not require concomitant therapy with psychotropic medication.
- Must not be currently dependent on other substances, with the exception of nicotine
or caffeine.
- Hypersensitivity to buspirone or any other product component.
- Patients who, in the investigator's opinion, would be unable to comply with study
procedures or assessments, or would be unacceptable study candidates (e.g., poses
threat to staff).
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
